Neovascular age-related macular degeneration (nAMD), also known as wet AMD, is one of the leading causes of severe vision loss among the aging population worldwide. Characterized by abnormal blood vessel growth beneath the retina, the condition requires timely and effective treatment to prevent irreversible blindness. With continuous innovation in ophthalmic therapeutics, the neovascular age-related macular degeneration treatment market is witnessing robust growth and renewed clinical focus.

Market Overview

The neovascular age-related macular degeneration treatment market was valued at USD 11.83 Billion in 2025 across the 7 major markets. Supported by rapid advancements in biologics and targeted therapies, the market is expected to grow at a CAGR of 7.50% during the forecast period of 2026–2035, reaching a projected value of USD 24.38 Billion by 2035. The expansion reflects rising disease prevalence, improved diagnosis rates, and the long-term nature of treatment.

Key Market Drivers

Several factors are contributing to the steady expansion of the nAMD treatment market:

Rising aging population: Increasing life expectancy globally is directly contributing to higher nAMD incidence rates.

Advancements in anti-VEGF therapies: Continuous improvements in anti-vascular endothelial growth factor (anti-VEGF) drugs are enhancing treatment efficacy and durability.

Growing awareness and early diagnosis: Improved access to ophthalmic screening and patient awareness campaigns are enabling earlier intervention.

Strong R&D pipeline: Ongoing clinical trials focusing on longer-acting formulations and novel mechanisms of action are fueling future growth.

Treatment Landscape Insights

Anti-VEGF injections remain the gold standard for treating neovascular AMD, accounting for the largest share of the market. These therapies help slow disease progression and preserve vision by inhibiting abnormal blood vessel growth. Emerging therapies, including sustained-release implants and combination treatments, aim to reduce treatment burden and improve patient adherence.

Hospital ophthalmology departments and specialized eye clinics are the primary end users, given the need for specialized administration and monitoring.

Regional Perspective

The 7 major markets, including the United States, Europe, and Japan, dominate the global nAMD treatment landscape due to strong reimbursement frameworks, high healthcare spending, and rapid adoption of innovative therapies. Continued regulatory approvals and guideline updates are expected to sustain market momentum in these regions.

Request your complimentary sample report featuring the complete TOC.

Competitive Landscape

The market is highly competitive, with leading pharmaceutical companies focusing on innovation, strategic partnerships, and lifecycle management. Prominent players include:

F. Hoffmann-La Roche Ltd

Bausch & Lomb

Novartis AG

Pfizer, Inc.

AbbVie Inc.

Santen Pharmaceutical Co., Ltd.

Ophthotech Corporation

Alimera Sciences

GSK plc

Bayer AG